Radionuclide Molecular Imaging in Heart Failure

The prevalence of heart failure (HF) continues to increase, and with an estimated 825,000 new cases annually in the U.S., the burden will continue to rise, expected to exceed eight million by 2030.1 Mortality in patients with HF is considerable, with over 50% dying within five years of diagnosis.1 The mortality rate has improved slightly in the last few years but continues to be excessive. With over one million hospital discharges annually and costs exceeding $30 billion per year, improved ways to evaluate, prognosticate, and potentially determine effectiveness of therapies is necessary to improve the burden of HF.1

Systolic HF is a progressive disease manifesting in a complex of decreased cardiac output, decreased organ perfusion, volume overload and neurohormonal imbalance. In addition, there are a variety of changes that occur at a cellular and molecular level that affect myocardial function, remodeling, and progression of disease. Part of the challenge of treating HF patients is determining which patients will deteriorate, which are at risk of arrhythmias, and who will respond to particular therapies. Radionuclide imaging has traditionally been used to evaluate the etiology of HF, whether ischemic or non-ischemic and to determine the extent and severity of ischemia. The field of radionuclide imaging is broadening, and in addition to anatomical imaging, radionuclide imaging also has the unique ability to image the myocardium at a molecular level. This molecular imaging is designed to image the spectrum of cardiovascular disease including inflammation, thrombosis, apoptosis, necrosis, and fibrosis.2 Additionally, radionuclide imaging can assess the sympathetic innervation of the myocardium. In HF, the autonomic nervous system is disrupted, initially with upregulation of the sympathetic nervous system to compensate for a failing heart and, over time, downregulation of cardiac receptors. Currently, cardiac sympathetic innervation can be imaged with the norepinephrine (NE) analogue, iodine-123-meta-iodobenzylguanidine (123I-mIBG). Sympathetic innervation imaging can provide insights into the prognosis of patients with HF and, in the future, may evolve into a prognostic tool to help risk stratify patients who will benefit from particular interventions including device therapy.

Cardiac Autonomic Innervation

The autonomic nervous system plays in an important role in regulating cardiac function and consists of circulating hormones, such as NE, and direct neural control by sympathetic and parasympathetic cardiac innervation. It is now possible to image sympathetic cardiac innervation with a radiolabeled NE analogue. As illustrated in Figure 1, NE is synthesized in presynaptic adrenergic terminals and stored in vesicles that, in response to sympathetic stimuli, are released into synaptic spaces and interact with postsynaptic α, β1 and β2-receptors on the myocyte membrane resulting in heart rate, contractility and conduction effects.3 To control and terminate these effects, there is active NE reuptake into presynaptic terminals, mostly via the norepinephrine transporter-1 (NET1) membrane protein, for storage or catabolic metabolism.4 Iodine-123-meta-iodobenzylguanidine (123I-mIBG) is a radiolabeled analogue of the false NE transmitter guanethidine that, when injected intravenously, diffuses into synaptic spaces and is taken up into presynaptic terminals by the NET1 transporter but not metabolized, thereby accumulating and allowing imaging for assessment of the functional state of adrenergic innervation.5

Figure 1

Figure 1

Schematic representation of the sympathetic neuron synapse. In response to a stimulus, vesicles containing norepinephrine are released into the synaptic space and interact with post-synaptic receptors. AC = adenyl cyclase; AMP = adenosine monophosphate; cAMP = cyclic adenosine monophosphate; G = G proteins; NE = norepinephrine.
Reproduced with permission from Travin MI. Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin 2009;27:311-27.

Cardiac 123I-mIBG imaging involves a rest injection of 10 mCi (patient exposure is ~ 5 mSv), followed by early and ~4-hour delayed anterior planar images, and often tomographic images as well. 123I-mIBG imaging is frequently accompanied by rest perfusion imaging at another time to relate regional adrenergic function to perfusion. Imaging is by a conventional gamma camera focused on the principal 159 keV 123I-emission using a low energy collimator, although there are reports suggesting that use of a medium energy collimator to block corrupting higher energy emissions may be better.6 There is early data of imaging with solid state cameras, although different quantitative parameters result.7

Currently the most important parameter assessed is global cardiac uptake in reference to background, i.e., the heart-to-mediastinum ratio (HMR). Based on reports of control subjects, a normal HMR is 2.2 ± 0.3, from which an HMR more than 2 standard deviations below (i.e., <1.6) has been used as a threshold for increased risk of adverse events,8 although there is a continuous gradient of increased risk as the HMR decreases below normal.9 While there are reports of 123I-mIBG imaging being useful in a variety of cardiac pathologies including myocardial ischemia,10 primary arrhythmic conditions (e.g., Brugada syndrome11 and arrhythmogenic right ventricular dysplasia12), post-cardiac transplant,13 assessing myocardial damage from diabetes mellitus,14 and determining cardiac effects of cancer chemotherapy,15 the current focus is on HF and associated arrhythmias. Potential use of 123I-mIBG for risk stratifying patients with HF was demonstrated in a key study by Merlet et al. showing HMR to be more powerful and independent of cardiac size, echocardiographic end-diastolic diameter and left ventricular ejection fraction (LVEF) in predicting survival.16 Over about two decades, single-center studies demonstrated the robustness of the HMR for risk stratifying patients with HF, leading to the prospective multicenter international AdreView Myocardial Imaging for Risk Evaluation in Heart Failure (ADMIRE-HF) study of 961 patients with New York Heart Association (NYHA) Class II-III HF and LVEF ≤35%, in which an HMR <1.6 more than doubled the occurrence of worsening NYHA class, life-threatening arrhythmias, and cardiac death, with a hazard ratio (for a higher HMR), of 0.40 (p <0.001).17 Key results of this study are shown in Figure 2. Multivariate analysis showed that HMR predicts cardiac and all-cause deaths independent of other variables, including age, NYHA class, LVEF, and brain natriuretic peptide (BNP). A substudy showed that HMR added to the Seattle Heart Failure model for predicting survival, with a net reclassification improvement of 22.7%.18 A study of 1,322 patients from six Japanese centers re-analyzing previous prospectively collected data found similar results to ADMIRE-HF.19 Figure 3 shows examples of 123I-mIBG images in patients with HF.

Figure 2

Figure 2

ADMIRE-HF Kaplan-Meier event curves comparing subjects with HMR <1.60 versus ≥1.60.
A) Composite events including HF progression (increase in NYHA functional class), potentially life-threatening arrhythmic events, and cardiac death. Most events (about 2/3) were HF progression. B) Cardiac death in relation to HMR, showing an extremely low 24-month (only 2 out of 192 patients) death occurrence for patients with HMR ≥1.6. ADMIRE-HF = AdreView Myocardial Imaging for Risk Evaluation in Heart Failure; HF = heart failure; HMR = heart to mediastinum ratio; NYHA = New York Heart Association.
Reproduced with permission from Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.

Figure 3

Figure 3

Examples of planar 123I-mIBG images in patients with HF with HMRs and patient outcomes described.

  1. 79-year-old male with nonischemic NYHA II HF and LVEF of 35%. HMR = 2.02. No cardiac event over five-year follow-up.
  2. 64-year-old female with nonischemic NYHA III HF and LVEF 25% - 30%. HMR = 1.38. Experienced numerous arrhythmic events/ICD discharges over the next two years, requiring VT ablation.
  3. 28-year-old male with non-ischemic NYHA II HF and LVEF = 20%. HMR = 1.17 (cardiac uptake is barely above background). Progressed within one year from NYHA II to NYHA III.

HF = heart failure; HMR = heart to mediastinum ratio; ICD = implantable cardioverter defibrillator; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; VT = ventricular tachycardia.

Nevertheless, risk stratification is insufficient for demonstrating clinical utility, with the need to show utility in guiding therapy. HMR can help monitor the clinical course of patients on standard HF medications,20-23 but as HMR is unlikely to significantly influence the use of such medications, an area of investigation has been potential use of 123I-mIBG to guide invasive, expensive therapies. As a deteriorating HMR while on comprehensive medical therapy indicates a poor prognosis,24 some have suggested that 123I-mIBG imaging could help select patients needing interventions such as cardiac resynchronization therapy,25 a left ventricular assist device (LVAD), or cardiac transplantation.26,27 A few small studies have shown that 123I-mIBG imaging may help select LVAD patients who are improving sufficiently to defer potential transplant and perhaps explant the device.28,29

A major focus has been on the ability of 123I-mIBG imaging to risk stratify patient for risk of ventricular arrhythmic sudden cardiac death (SCD), and thereby guide the use of an implantable cardioverter defibrillator (ICD).30 While guidelines recommend LVEF (≤35%) as a key criterion for implanting an ICD,31 there are limitations to this approach.32,33 As many patients with an ICD do not use it, and as the device is costly and has potentially serious complications,34 clinicians are often not following guidelines35 indicating that a better approach is desirable.36 As cardiac autonomic innervation is more closely related to underlying mechanisms of arrhythmias than LVEF,37 123I-mIBG imaging should better determine the need for an ICD. Studies report that 123I-mIBG parameters, including HMR,38,39 washout,40 and regional single-photon emission computed tomography (SPECT) defects41 identify patients at higher risk of lethal arrhythmias. ADMIRE-HF found that patients with HMR ≥1.6 had an extremely low risk of lethal arrhythmic events over a two-year follow-up.17 The ability of tomographic imaging to identify regional defects may make it more specific than planar HMR for identifying arrhythmic risk.27,42 Supporting this concept is a recent study using the similar adrenergic PET tracer 11C-hydroxyephedrine (11C-HED) in 200 patients with ischemic cardiomyopathy, showing that four-year occurrence of lethal/potentially lethal arrhythmic events increased in relation to the severity/extent of 11C-HED tomographic abnormalities independent of BNP, symptoms, or LVEF.43

Nevertheless, it is the consensus in the cardiology community that well designed prospective studies must be undertaken before 123I-mIBG imaging can supplant established ICD guidelines. In lieu of such studies, among indications that could conceivably be supported at the present time (although there are no specific data) are 1) patients with HF with LVEF≤35%, NYHA Class II, III who meet established American College of Cardiology (ACC)/American Heart Association (AHA) Class I indication for ICD placement and have not received ICD due to uncertainty on the part of the treating physician or the patient; 2) patients who originally received an ICD for primary or secondary prevention of SCD, who subsequently underwent complete device and lead removal due to definite infection, and there is uncertainty on the part of treating physician to proceed with ICD replacement; and 3) patients with HF who originally received an ICD for primary prevention of SCD when LVEF was <35%, have had no clinically relevant ventricular arrhythmias since implant, have had improvement of the LVEF, and require generator replacement. Development of registries has also been suggested as way of assessing practical clinical utility, but at the moment, product pricing in relation to third party reimbursement presents a major challenge.

References

  1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292.
  2. Sinusas AJ, Thomas JD, Mills G. The future of molecular imaging. JACC Cardiovasc Imaging 2011;7:799-806.
  3. Travin MI. Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin 2009;27:311-27.
  4. Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine pharmacology: pharmacology and clinical studies. Am J Physiol Imaging 1986;1:96-103.
  5. Wieland DM, Mangner TJ, Inbasekaran MN, et al. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 1984;27:149-55.
  6. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, Van Eck-Smit BL, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging 2005;32:1100-7.
  7. Rouzet F, Chequer RD, Milliner M, Ben Azzouna R, Mikail N, Askienazy S, Le Guludec D. Comparison of MIBG heart-to-mediastinum ratio determined on conventional and cardiac CZT camera. J Nucl Med 2014;55 (Supplement 1):133.
  8. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.
  9. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90.
  10. Tomoda H, Yoshioka K, Shiina Y, Tagawa R, Ide M, Suzki Y. Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina. Am Heart J 1994;128:452-8.
  11. Wichter T, Matheja P, Eckardt L, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002;105:702-6.
  12. Paul M, Wichter T, Kies P, et al. Cardiac sympathetic dysfunction in genotyped patients with arrhythmogenic right ventricular cardiomyopathy and risk of recurrent ventricular tachyarrhythmias. J Nucl Med 2011;52:1559-65.
  13. Bengel FM, Ueberfuhr P, Schiepel N, Nekolla SG, Reichart B, Schwaiger M. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med 2001;345:731-8.
  14. Nagamachi S, Fujita S, Nishii R, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2006;13:34-42.
  15. Carrió I, Estorch M, Berna L, López-Pousa J, Tabernero J, Torres G. Assessment of anthracycline-related myocardial adrenergic Indium- 111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-49.
  16. Merlet P, Valette H, Dubois-Randé J, et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med 1992;33:471-77.
  17. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
  18. Ketchum ES, Jacobson AF, Caldwell JH, et al. Selective improvement in Seattle heart failure model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol 2012;19:1007-16.
  19. Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of I-123-mIBG cardiac sympathetic innervation imaging for assessment of long-term prognosis in chronic heart failure. JACC Cardiovasc Imaging 2013;6:772-84.
  20. Cohen-Solal A, Rouzet F, Berdeaux A, et al. Effects of carvedilol on myocardial sympathetic innervations in patients with chronic heart failure. J Nucl Med 2005;46:1796-803.
  21. Kasama S, Toyama T, Kumakura H, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81.
  22. Kasama S, Toyama T, Kumakura H. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved LVEF. J Am Coll Cardiol 2005;45:661-7.
  23. Gerson MC, Craft LL, McGuire N, Suresh DP, Abraham WT, Wagoner LE. Carvedilol improves left ventricular function in heart failure with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 2002;9:608-15.
  24. Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments – comparison with neurohumoral factors. Circ J 2002;66:537-43.
  25. D'Orio Nishioka SA, Filho MM, et al. Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol 2007;14:852-9.
  26. Gerson MC1, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 2003;9:384-91.
  27. Verschure DO, Veltman CE, Manrique A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging 2014;15:996-1003.
  28. Drakos SG, Athanasoulis T, Malliaras KG, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. JACC Cardiovasc Imaging 2010;3:64-70.
  29. George RS, Birks EJ, Cheetham A, et al. The effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 2013;15:1035-43.
  30. Gerson MC, Abdallah M, Muth JN, Costea AI. Will imaging assist in the selection of patients with heart failure for an ICD? JACC Cardiovasc Imaging 2010;3:101-10.
  31. Jessup M, Abraham WT, Casey DE, et al.. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;53:1343-82.
  32. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 2007;50:1150-7.
  33. Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med 2008;359:2245-53.
  34. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010;55:774-82.
  35. Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA 2011;305:43-9.
  36. Passman R, Kadish A. Shouldn't everyone have an implantable cardioverter-defibrillator? Circulation 2009;120:2166-7.
  37. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004;95:754-763.
  38. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31.
  39. Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-233.
  40. Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 Metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009;53:426-35.
  41. Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-Iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2769-77.
  42. Verberne HJ, Henzlova MJ, Jain D, et al. Regional myocardial mismatch between 123I-MIBG and 99mTc-tetrofosmin SPECT for the prediction of arrhythmic events in ischemic heart failure patients. J Nucl Cardiol 2014;21:799 (abstract).
  43. Fallavollita JA, Heavey BM, Luisi AJ, Jr., et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63:141-9.

Clinical Topics: Arrhythmias and Clinical EP, Cardiac Surgery, Cardio-Oncology, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Prevention, Implantable Devices, Genetic Arrhythmic Conditions, SCD/Ventricular Arrhythmias, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Lipid Metabolism, Novel Agents, Acute Heart Failure, Heart Failure and Cardiac Biomarkers, Heart Transplant, Mechanical Circulatory Support , Interventions and Imaging, Interventions and Structural Heart Disease, Computed Tomography, Nuclear Imaging

Keywords: 3-Iodobenzylguanidine, Adenosine Monophosphate, Adenylate Cyclase, Adrenergic Agents, American Heart Association, Apoptosis, Arrhythmogenic Right Ventricular Dysplasia, Autonomic Nervous System, Brugada Syndrome, Cardiac Resynchronization Therapy, Consensus, Cost of Illness, Death, Sudden, Cardiac, Defibrillators, Implantable, Diabetes Mellitus, Down-Regulation, Female, Follow-Up Studies, Gamma Cameras, Guanethidine, Heart Failure, Heart Transplantation, Heart Rate, Heart-Assist Devices, Humans, Inflammation, Iodine, Male, Mediastinum, Molecular Imaging, Multivariate Analysis, Myocardial Ischemia, Myocardium, Natriuretic Peptide, Brain, Neoplasms, New York, Norepinephrine, Norepinephrine Plasma Membrane Transport Proteins, Perfusion Imaging, Presynaptic Terminals, Prevalence, Primary Prevention, Prognosis, Prospective Studies, Radioisotopes, Receptors, Neurotransmitter, Registries, Secondary Prevention, Stroke Volume, Sympathetic Nervous System, Tachycardia, Ventricular, Thrombosis, Tomography, Emission-Computed, Single-Photon, Uncertainty, United States, Up-Regulation, Cardiotoxicity


< Back to Listings